文献速递肾小球疾病

多靶点多药物:补体介导肾小球疾病的新型治疗

Many drugs for many targets: novel treatments for complement-mediated glomerular disease.
PubMed 文献 · Nephrol Dial Transplant · 2017-01-01

本文综述补体激活在多种肾小球疾病中导致肾小球损伤的证据,指出不同疾病触发补体激活的机制不同:免疫复合物激活经典途径,部分疾病直接激活旁路途径和甘露糖结合凝集素途径。依库珠单抗为抗C5抑制性抗体,已获批用于治疗非典型溶血性尿毒症综合征,病例报告提示其对其他类型肾小球肾炎也可能有效。文章还讨论针对补体级联其他蛋白的新药研发、靶向不同蛋白的依据及临床转化面临的挑战。

要点

  • 不同肾小球疾病补体激活途径不同,治疗需按机制选择靶点
  • 依库珠单抗已获批用于非典型溶血性尿毒症综合征,其他肾小球肾炎仅见病例报告
  • 针对补体级联多个蛋白的新药在研,特异性阻断相关蛋白成为可能

核心结论

  • 补体激活参与多种肾小球疾病的肾小球损伤,但触发机制因病而异,针对补体级联特定蛋白的靶向治疗是发展方向。

研究设计与样本

  • 综述,总结实验与临床证据,讨论补体级联不同蛋白的靶向依据、在研抗补体药物及临床转化挑战。

主要发现

  • 免疫复合物在多种肾小球肾炎中激活经典途径,部分疾病直接激活旁路途径和甘露糖结合凝集素途径。
  • 依库珠单抗为抗C5抑制性抗体,已获批治疗非典型溶血性尿毒症综合征。
  • 病例报告提示依库珠单抗对其他类型肾小球肾炎也可能有效。
  • 针对补体级联其他蛋白的新抗补体药物正在研发中。

临床怎么用

  • 依据不同肾小球疾病的补体激活途径选择相应靶点的补体抑制治疗。
  • 依库珠单抗用于非典型溶血性尿毒症综合征有获批依据,用于其他肾小球肾炎目前仅有病例报告支持。

局限性

  • 本文为综述,未提供新的原始研究数据。
  • 依库珠单抗对其他类型肾小球肾炎的疗效仅有病例报告,缺乏系统证据。
  • 新型抗补体药物尚在研发阶段,临床转化仍面临挑战。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

There is a large body of experimental and clinical evidence that complement activation contributes to glomerular injury in multiple different diseases. However, the underlying mechanisms that trigger complement activation vary from disease to disease. Immune complexes activate the classical pathway of complement in many types of glomerulonephritis, whereas the alternative pathway and mannose-binding lectin pathways are directly activated in some diseases. Eculizumab is an inhibitory antibody to C5 that has been approved for the treatment of atypical hemolytic uremic syndrome, and case reports suggest that it is also effective in other types of glomerulonephritis. Furthermore, new complement-inhibitory drugs are being developed that target additional proteins within the complement cascade, raising the possibility of blocking the specific complement proteins involved in a given disease. This review examines the rationale for targeting different proteins within the complement cascade, the new anti-complement drugs currently in development and some of the challenges that investigators will face in bringing these drugs to the clinic.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Thurman JM. Many drugs for many targets: novel treatments for complement-mediated glomerular disease. Nephrol Dial Transplant. 2017. PMID: 28391332. doi:10.1093/ndt/gfw228

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。